However, despite the well‐established role of PARP‐1 activation in the development of various inflammatory conditions—including pulmonary inflammation and cardiovascular disease—PARP‐1 inhibition by Au(I) compounds has never been considered among their mechanisms of action in rheumatoid arthritis. This evidence concerns the gene PARP1 and cardiovascular disorder.